Literature DB >> 12436477

Ribavirin inhibits DNA, RNA, and protein synthesis in PHA-stimulated human peripheral blood mononuclear cells: possible explanation for therapeutic efficacy in patients with chronic HCV infection.

Volker Meier1, Erik Bürger, Sabine Mihm, Bernhard Saile, Giuliano Ramadori.   

Abstract

The treatment of choice for patients infected chronically with HCV is the combination of IFN-alpha and ribavirin. Monotherapy with ribavirin leads to a clinical and histological improvement, but its exact mechanism of action is unknown. Therefore, the effect of ribavirin on synthesis of inflammatory cytokines and on apoptosis in stimulated peripheral blood mononuclear cells (PBMCs) was investigated. PBMCs were isolated from the blood of HCV infected patients and from healthy volunteers. The effect of ribavirin on IFN-gamma and IL-1beta release in the supernatant of unstimulated and phytohemagglutinin (PHA) stimulated PBMCs was investigated by enzyme linked immunosorbent assay (ELISA). The effect on total DNA, RNA, and protein synthesis was analyzed by measurement of 3H-thymidine, 3H-uridine and 3H-leucine incorporation into cellular macromolecules. Ribavirin led to a dose-dependent decrease of the IFN-gamma but an increase of IL-1beta release into the supernatant of PHA-stimulated PBMCs. At the same time, a dose-dependent decrease of total DNA, RNA, and protein synthesis in cultures of PHA-stimulated PBMCs was demonstrated. These effects could be compensated by the addition of equimolar amounts of guanosine. The rate of apoptotic CD45+ and CD14+ cells in PBMCs cultures increased in a dose-dependent manner. Our data suggest that ribavirin administration to chronically HCV-infected patients could lead to a decrease of the synthesis of proinflammatory cytokines (e.g., IFN-gamma) by an inhibition of total DNA-, RNA-, and protein-synthesis and by induction of apoptosis in the cells of the inflammatory infiltrate. Furthermore, ribavirin could influence the synthesis of viral particles in the hepatocytes. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12436477     DOI: 10.1002/jmv.10264

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

Review 1.  Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels.

Authors:  Gillian M Keating; Greg L Plosker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection.

Authors:  Greg L Plosker; Gillian M Keating
Journal:  Drugs       Date:  2004       Impact factor: 9.546

3.  Impact of alpha interferon and ribavirin on the function of maturing dendritic cells.

Authors:  Eleanor Barnes; Mariolina Salio; Vincenzo Cerundolo; Joanne Medlin; Shona Murphy; Geoffrey Dusheiko; Paul Klenerman
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

Review 4.  Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C.

Authors:  Gillian M Keating; Monique P Curran
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Serum hepatic enzyme manifestations in patients with severe acute respiratory syndrome: retrospective analysis.

Authors:  Hui-Juan Cui; Xiao-Lin Tong; Ping Li; Ying-Xu Hao; Xiao-Guang Chen; Ai-Guo Li; Zhi-Yuan Zhang; Jun Duan; Min Zhen; Bin Zhang; Chuan-Jin Hua; Yue-Wen Gong
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

6.  Effect of ribavirin alone or combined with silymarin on carbon tetrachloride induced hepatic damage in rats.

Authors:  Omar M E Abdel Salam; Amany A Sleem; Enayat A Omara; Nabila S Hassan
Journal:  Drug Target Insights       Date:  2007-02-07

7.  Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC).

Authors:  Rahul Gupta; Sun Kim; Milton W Taylor
Journal:  J Transl Med       Date:  2012-03-22       Impact factor: 5.531

8.  Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin.

Authors:  Dale L Barnard; Craig W Day; Kevin Bailey; Matthew Heiner; Robert Montgomery; Larry Lauridsen; Scott Winslow; Justin Hoopes; Joseph K-K Li; Jongdae Lee; Dennis A Carson; Howard B Cottam; Robert W Sidwell
Journal:  Antiviral Res       Date:  2006-03-24       Impact factor: 5.970

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.